Membrane-permeable NFAT inhibitory peptide

Details Membrane-permeable NFAT inhibitory peptide Membrane-permeable NFAT inhibitory peptide

2006-12-05

2010-02-09

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S324000, C530S333000

Reexamination Certificate

active

07659249

ABSTRACT:
The present invention aims to solve the conventional problems by providing a peptide compound, in which when administered to a patient of immunologic disease, cardiac hypertrophy or a disease caused by NFAT activation, the period from administration to actual exhibition of effectiveness is short and there are no side effects or antigenicity. Specifically, the present invention relates to a membrane permeable NFAT inhibitory peptide comprising several consecutive arginines and a NFAT-activity inhibitory peptide sequence; a NFAT activation inhibitory agent comprising the peptide; and a immunosuppressive agent and cardiac hypertrophy suppressive agent, comprising the peptide compound as the active ingredient.

REFERENCES:
patent: 5981279 (1999-11-01), Weiss
patent: 6982082 (2006-01-01), Schreiber et al.
patent: 2002-153288 (2002-05-01), None
patent: WO 01/43694 (2001-06-01), None
patent: WO 03/006619 (2003-01-01), None
Aramburu J. et al., “Affinity-Driven Peptide Selection of an NFAT Inhibitor More Selective Than Cyclosporin A”, Science, American Association for the Advancement of Science, US, vol. 285, Sep. 24, 1999, pp. 2129-2133, XP 002939935.
Lindgren M. et al., “Cell-Penetrating Peptides”, Trends in Pharmacological Sciences, Elsevier, Haywarth, GB, vol. 21, No. 3, Mar. 2000, pp. 99-103, XP002290884.
Noguchi H. et al., “A New Cell-Permeable Peptide Allows Successful Allogeneic Islet Transplantation in Mice”, Nature Medicine, vol. 10, No. 3, Mar. 2004, pp. 305-309, XP002351236.
Supplementary European Search Report dated Nov. 9, 2005.
C. Loh, et al., J. Biol. Chem. (1996) 271 (18), pp. 10884-10891.
E. S. Scott, et al., J. Virol. (2001) 75(20), pp. 9955-9965.
M. Matsushita, et al,. J. Neurosci. (2001) 21 (16), pp. 6000-6007.
A. M. Ho, et al., J. Biol Chem. (1994) 269(45), pp. 28181-28186.
T. C. Foster, et al., J. Neurosci. (2001) 21(11), pp. 4066-4073.
Li Hua Jin et al.; “Transduction of Human Catalase Mediated by an HIV-1 TAT Protein Basic Domain and Arginine-Rich Peptides into Mammalian Cells”; Free Radical Biology & Medicine, vol. 31, No. 11, pp. 1509-1519; Dec. 1, 2001.
Donna M. Berry et al.; “Caspase-Dependent Cleavage of the Hematopoietic Specific Adaptor Protein Gads Alters Signalling from the T Cell Receptor”; Oncogene; vol. 20; pp. 1203-1211; Mar. 8, 2001.

Affiliated with

Also associated with

Rating

Membrane-permeable NFAT inhibitory peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Membrane-permeable NFAT inhibitory peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Membrane-permeable NFAT inhibitory peptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4231781